Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Squamous Cell Carcinoma of Head and Neck 25Head and Neck Neoplasms 17Salivary Gland Neoplasms 5Oropharyngeal Neoplasms 4Nasopharyngeal Carcinoma 4Melanoma 4Carcinoma, Renal Cell 4Sarcoma 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Recurrent Head and Neck Carcinoma 2Mouth Neoplasms 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Squamous Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Spinal Cord Compression 1Skin Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms, Squamous Cell 1Neoplasms 1Neoplasm Metastasis 1Laryngeal Diseases 1Kidney Neoplasms 1

Interventions

Cisplatin 29Magnetic Resonance Spectroscopy 16Specimen Handling 13Radiotherapy 12pembrolizumab 11Radiotherapy, Intensity-Modulated 11Cetuximab 11Surgical Procedures, Operative 9Paclitaxel 9Fluorouracil 9Docetaxel 9Platinum 81,2-diaminocyclohexaneplatinum II citrate 8Radiation 6Carboplatin 6Taxes 5Biopsy 5toripalimab 4X-Rays 4Surveys and Questionnaires 4Fluorodeoxyglucose F18 4Chemoradiotherapy 4Celecoxib 4(225)Ac-DOTA-c(RGDyK) 4Immunohistochemistry 3Counseling 3130-nm albumin-bound paclitaxel 3motexafin gadolinium 2ipatasertib 2camrelizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hypopharyngeal Neoplasms × Radiosurgery × Head & Neck × Clear all
NCT07156227 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
39 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04576091 2024-12-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
7 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡